Primary Ciliary Dyskinesia 47 and Lissencephaly

1. Disease Information

Overview: Primary Ciliary Dyskinesia-47 and Lissencephaly (CILD47) is an ultra-rare autosomal recessive disorder caused by biallelic loss-of-function variants in TP73 (the p53-family transcription factor gene). It combines a motile-ciliopathy respiratory phenotype (chronic mucociliary clearance failure) with a neurodevelopmental phenotype (anterior-predominant lissencephaly/pachygyria with corpus callosum abnormality). Mechanistically it is not a classic axonemal-structure PCD but belongs to the "reduced generation of multiple motile cilia" (RGMC) subgroup — a defect in the transcriptional program that specifies multiciliated cell (MCC) differentiation itself, analogous to MCIDAS-, CCNO-, and FOXJ1-related disease, rather than a defect of the assembled axoneme (Wallmeier et al. 2021, PMID:34077761).

Key identifiers: - OMIM phenotype: #619466 — "Ciliary dyskinesia, primary, 47, and lissencephaly (CILD47)" - OMIM gene: 601990 — TP73 (tumor protein p73) - Gene location: 1p36.32 (HGNC:12003; NCBI Gene ID 7161) - MONDO/Orphanet: No independently verified MONDO or dedicated Orphanet ID was found in this search; the condition is recent (2021) and may only be indexed under a general PCD/RGMC or OMIM-derived term. This should be explicitly checked with OAK/MONDO lookup before curation rather than assumed. - Inheritance: Autosomal recessive - Distinguish from "isolated" lissencephaly (LIS1/PAFAH1B1, DCX, TUBA1A etc.) — TP73-lissencephaly is a syndromic, ciliopathy-associated* lissencephaly, mechanistically and radiologically distinct (see §6, §7).

Synonyms/alternative names: "TP73-related mucociliary clearance disorder and lissencephaly"; "CILD47"; occasionally described under the umbrella term "reduced generation of multiple motile cilia (RGMC) with lissencephaly."

Evidence basis: All currently published human data derive from a single case series — 7 affected individuals from 5 unrelated, mostly consanguineous families (Wallmeier et al. 2021, Am J Hum Genet 108(7):1318–1329, PMID:34077761) — supplemented by extensive mouse-model mechanistic literature on Trp73/TAp73 in ciliated epithelia (see §6, §15). This is aggregated disease-level case-series data, not large-cohort or EHR-derived data — sample size is a fundamental limitation for all epidemiological/prognostic claims below.

2. Etiology

Disease causal factor: Purely genetic — biallelic (homozygous or compound heterozygous) loss-of-function variants in TP73, disrupting both major isoform classes (TAp73, the N-terminally intact transactivating isoform, and ΔNp73, the N-terminally truncated isoform), resulting in complete TP73 protein deficiency (PMID:34077761).

Genetic risk factors: - Biallelic TP73 null alleles are causal and (based on the reported families) appear fully penetrant for the respiratory+CNS phenotype. - Consanguinity is a major risk factor observationally — "most families showed consanguinity" in the founding cohort (PMID:34077761), consistent with an autosomal recessive, presumably ultra-rare allele model with regional/familial enrichment rather than a common founder variant. - No modifier genes have yet been reported; genotype-phenotype correlation across the 5 families is not yet resolved (small n).

Environmental/lifestyle risk factors: None identified or plausible — this is a monogenic transcription-factor deficiency, not a multifactorial or exposure-modulated disease. No gene-environment interaction data exist.

Protective factors: None described. Heterozygous carriers (unaffected parents in all reported families) show no reported phenotype, consistent with recessive, non-haploinsufficient inheritance for this disease (distinct from TP73's proposed, unrelated, monoallelic-expression/tumor-suppressor role in neuroblastoma, which is a separate biological context — see §4).

3. Phenotypes

Respiratory phenotype (present in all 7 reported patients)

Neurological/CNS phenotype (present in all 7 reported patients)

Severity/progression: The lissencephaly and hypotonia/cognitive impairment are static developmental-malformation phenotypes; the respiratory disease is chronic and can progress to bronchiectasis and, in the most severe neonatal-onset cases, fatal respiratory failure. Frequency is based on n=7, so all frequency bands should be treated with caution (dismech convention: prefer qualitative framing over fabricated FREQUENT/OCCASIONAL percentages absent a larger cohort, per the project's frequency-evidence SOP).

Quality of life: No formal QoL instrument (EQ-5D, SF-36) data exist for this specific disease; impact is inferable as substantial (ventilator dependency in infancy, chronic lung disease, moderate–severe developmental impairment) but not separately quantified in the literature.

4. Genetic/Molecular Information

Causal gene: TP73 (HGNC:12003, NCBI Gene 7161, OMIM *601990), chromosome 1p36.32.

Reported pathogenic variants (all homozygous, all predicted loss-of-function, disrupting both TAp73 and ΔNp73 isoforms; from Wallmeier et al. 2021, PMID:34077761): 1. Homozygous deletion spanning exons 7–14 (~13.17 kb) — family OP-1693 2. c.1196+1G>A (canonical splice-donor variant, intron retention → premature stop) — families OP-3039 and KI-645 3. c.1459delT, p.Tyr487Thrfs11 (frameshift) — family 19DG0120 4. c.994C>T, p.Gln332 (nonsense) — families 18DG0963 and 19DG2776 (cousins) 5. c.613G>T, p.Glu205* (nonsense) — family 20DG1336

Variant classification: All variants would be classified pathogenic/likely pathogenic under ACMG/AMP criteria (null variant in a gene where LOF is an established disease mechanism, segregation in affected homozygotes, absence/rarity in population databases — gnomAD-level allele frequency data for these specific alleles were not retrieved in this search and should be checked directly against gnomAD before curation).

Functional consequence: Complete loss of TP73 protein function (both isoforms) → failure of the TAp73-driven multiciliogenesis transcriptional program (see §6).

Somatic vs. germline: Germline only — this is a constitutional Mendelian disorder, unrelated to TP73's somatic tumor-suppressor role in cancers (note: TP73/1p36 is also studied as a candidate tumor-suppressor locus in neuroblastoma and other cancers via a distinct, monoallelic-expression mechanism — that biology is not relevant to CILD47 and should not be conflated in curation).

Modifier genes: None established.

Epigenetics: No disease-specific DNA methylation/chromatin data for TP73-CILD47 were found. Note the general biology: TAp73 itself acts as a master transcriptional activator (not a chromatin modifier per se) of the multiciliogenesis network (FOXJ1, RFX2, RFX3, miR-34bc, and ~50 structural/functional ciliary genes) — see §6.

Chromosomal abnormalities: The exon 7–14 deletion in one family is effectively a small structural (contiguous-gene-region) deletion but confined to TP73 itself; no evidence of a broader 1p36 deletion syndrome phenotype overlap was reported.

HGNC/gene ontology suggestions: Gene: hgnc:12003 (TP73). Relevant GO molecular function: GO:0003700 (DNA-binding transcription factor activity); GO:0006355 (regulation of DNA-templated transcription).

5. Environmental Information

No environmental, occupational, toxin, dietary, lifestyle, or infectious-agent contributory factors have been described — this is a monogenic developmental/ciliopathy disorder. Recurrent respiratory infections are a consequence of impaired mucociliary clearance (secondary, not causal), typically involving common respiratory pathogens (e.g., Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus) as seen generally in PCD/chronic suppurative lung disease, though pathogen-specific data for this particular gene defect were not reported in the primary paper.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger: Biallelic TP73 LOF → complete loss of TAp73 (and ΔNp73) protein.
2. Transcriptional failure: TAp73 normally acts as the central transcriptional regulator of the multiciliogenesis program, acting downstream of MCIDAS and upstream of FOXJ1, within the Notch1-dependent multiciliated-cell (MCC) differentiation pathway. TAp73 directly activates FOXJ1, RFX2, RFX3, miR-34b/c, and ~50 structural/functional ciliary genes (Nemajerova et al. 2016, Genes Dev 30(11):1300, PMID:27257214; a companion paper — Fernández-Alonso, Buscà, et al., PMID:27298333 — independently converged on the same conclusion; Marshall et al. 2016, Cell Rep 14(14):2289–300, PMID:26947080).
3. Cellular consequence — failure of MCC differentiation: In TP73-deficient human airway epithelial (ALI) cultures: severely reduced FOXJ1-positive and RFX2-positive nuclei; severely reduced numbers of ciliated cells (~20–30% apical MCC coverage vs. ~73% in controls, p<0.0001); markedly shortened residual cilia (~1.5–1.8 µm vs. ~3.8 µm in controls, p<0.0001); occasional basal-body mislocalization within the cytoplasm; and a broader epithelial differentiation defect (epithelial layer height 7–10 µm/2 cell layers vs. 39.9 µm/6 layers in controls) (PMID:34077761).
4. Functional consequence — impaired mucociliary transport: Particle-tracking assays showed severely reduced transport velocity and directionality, i.e., a physiologically defective mucociliary escalator — despite grossly normal axonemal ultrastructure by electron microscopy (9+2 microtubule arrangement intact; outer dynein arms/DNAH5 and nexin-dynein regulatory complex/GAS8 correctly localized) (PMID:34077761). This distinguishes CILD47 mechanistically from "classical" structural PCD (e.g., DNAH5, CCDC39/40 mutants) — the defect is in generating enough normal cilia, not in cilia that are structurally abnormal.
5. Clinical respiratory consequence: Chronic impaired mucociliary clearance → recurrent airway infection, bronchiectasis, and (in severe neonatal cases) respiratory failure.
6. Parallel CNS consequence: TP73/TAp73 also governs multiciliogenesis and planar cell polarity (PCP) of brain ependymal cells and is required for proper corticogenesis. Mouse Trp73-null models show ependymal ciliary and PCP defects, hydrocephalus, hippocampal dysgenesis, and cortical lamination/subventricular-zone (SVZ) architecture abnormalities (Fatt/Gonzalez-Cano et al. lineage of studies: "p73 is required for ependymal cell maturation and neurogenic SVZ cytoarchitecture"; Fuertes-Álvarez et al. 2018, Cell Death Dis 9(2):163, "p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton," PMID not independently confirmed in this pass — verify before citing; Fujitani et al. 2017, Sci Rep 7:12007, "Loss of p73 in ependymal cells during the perinatal period leads to aqueductal stenosis," PMID:28931858). In humans, this maps onto the observed cortical malformation (anterior pachygyria/lissencephaly with corpus callosum hypoplasia/agenesis) — the authors propose that loss of the same TAp73-driven multiciliogenesis/cytoskeletal program that builds airway MCCs also disrupts a cilia-related process needed for normal neuronal migration/cortical layering, unifying the dual-organ phenotype under one mechanism rather than two independent gene functions (PMID:34077761).

Cell types involved: - Airway multiciliated epithelial cells (MCCs) — CL:0002145 (ciliated columnar cell of tracheobronchial tree) or CL:1000271 (lung ciliated cell) - Brain ependymal cells (ciliated, line the ventricles) — CL:0000065 (ependymal cell) - Cortical neurons / radial glia (migration defect substrate) — CL:0000679 (glutamatergic neuron), CL:0002608 (radial glial cell)

Suggested GO biological process terms: - GO:0035082 (axoneme assembly) — indirectly, via reduced ciliogenesis - GO:0007368 (determination of left/right symmetry) — notably not disrupted (situs solitus preserved), useful negative annotation - GO:0060271 (cilium assembly) - GO:0021987 (cerebral cortex development) / GO:0021795 (cerebral cortex cell migration) - GO:0003356 (regulation of cilium beat frequency involved in ciliary motility) — downstream functional consequence

Subcellular: Basal body (GO:0005930 cilium; GO:0032391 photoreceptor connecting cilium is not relevant); centriole/basal body mislocalization is a described cell-biology finding, though core basal-body number was preserved (distinguishing from CCNO/MCIDAS-driven centriole-amplification failure — a related but mechanistically distinct RGMC subtype).

Omics: No transcriptomic (GEO/ArrayExpress), proteomic, or single-cell datasets specific to human TP73-CILD47 patient tissue were identified in this search; the mechanistic transcription-factor-network data (FOXJ1/RFX2/RFX3/miR-34bc target network) derive primarily from mouse/organoid TAp73 ChIP and knockout transcriptomic studies (PMID:27257214, PMID:26947080).

7. Anatomical Structures Affected

Organ level: - Primary: Respiratory tract (nasal/paranasal sinuses, middle ear, trachea, bronchi, lung parenchyma via airway disease) and central nervous system (cerebral cortex, corpus callosum, hippocampus). - Secondary/complication-level: Lower respiratory tract structural damage (bronchiectasis) as a consequence of chronic infection. - Body systems: Respiratory system and nervous system are the two systems with a documented human phenotype; reproductive system (efferent duct multiciliogenesis, sperm flagella) is affected in other MCIDAS/CCNO/GEMC1 RGMC-family diseases and in Trp73 mouse models (sterility), but human fertility data specific to TP73-CILD47 were not reported (patients are pediatric in the reported cohort).

Tissue/cell level: - Respiratory pseudostratified ciliated epithelium (multiciliated cells) — UBERON:0002185 (bronchial epithelium), UBERON:0001707 (nasal cavity epithelium) - Ependymal lining of brain ventricles — UBERON:0002316 (ependyma) - Cerebral cortex (neuronal migration substrate) — UBERON:0000956 (cerebral cortex); UBERON:0002336 (corpus callosum) - Hippocampus — UBERON:0002421

Subcellular: Cilium/axoneme (GO:0005929 cilium), basal body (GO:0005930).

Localization/laterality: Situs solitus preserved (no laterality defect) — an important distinguishing negative finding from classical axonemal PCD, where left-right patterning defects (situs inversus/heterotaxy) are common because nodal cilia require normal axonemal dynein function; here nodal cilia function is apparently unaffected, consistent with a selective MCC-differentiation (not axonemal-structural) defect.

8. Temporal Development

• Onset: Congenital for the CNS malformation (developmental, present from birth/prenatally imageable); neonatal-to-early-childhood for respiratory disease onset — several patients presented with respiratory distress in the neonatal period requiring ventilatory support.
• Onset pattern: The CNS malformation is a fixed structural defect (not "progressive" in the neurodegenerative sense) but its functional consequences (developmental delay, hypotonia, seizure risk) manifest and are characterized over infancy/childhood. Respiratory disease is chronic and can be insidious/progressive (recurrent infections → bronchiectasis) or acute/severe from birth.
• Disease course: Chronic, lifelong for survivors (no described "remission"). One reported death (respiratory failure at 2 months) indicates a severe/fatal end of the phenotypic spectrum.
• Critical periods: Neonatal period is the highest-risk window for respiratory decompensation; prenatal/perinatal window is when the cortical malformation is established (developmental, not preventable postnatally).
• No formal staging system exists for this disease given its rarity.

9. Inheritance and Population

• Epidemiology: No dedicated prevalence/incidence estimate exists for CILD47 specifically — only 7 individuals from 5 families have been published (PMID:34077761); it should be treated as ultra-rare/case-series-only. For context, PCD as a whole has classically cited prevalence of ~1 in 10,000–20,000, though a 2022 population-genomic (carrier-frequency-based) analysis of pathogenic variants across 29 PCD genes estimated a much higher global prevalence of ~13.2 per 100,000 (Zariwala/Zhu et al., "The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants," PMID:35051411) — note TP73 was likely not among the "classical" 29 genes surveyed in earlier PCD gene panels given its 2021 discovery, so this estimate would not capture CILD47-specific carrier frequency.
• Inheritance pattern: Autosomal recessive.
• Penetrance: Appears complete/full in the reported homozygotes (all 7 affected).
• Expressivity: Variable — severity of both the respiratory phenotype (ranging from chronic infections to fatal neonatal respiratory failure) and the CNS phenotype (variable corpus callosum hypoplasia vs. agenesis, variable cognitive impairment severity) across the 7 patients.
• Consanguinity: A major contributing factor — most of the 5 founding families were consanguineous, consistent with a rare recessive allele being homozygosed via shared ancestry rather than a common population founder variant (contrast with, e.g., a single recurrent founder mutation).
• Founder effects: Not established; the 5 families carry 5 different (largely private) LOF alleles, arguing against a single dominant founder variant, though the c.994C>T (p.Gln332*) variant recurred in two related (cousin) families (18DG0963/19DG2776), consistent with a family-specific founder allele rather than population-wide.
• Carrier frequency: Not established for TP73 specifically.
• Population demographics: The reported cohort includes patients ascertained via clinical/genetic centers with Middle Eastern (Saudi Arabian — e.g., patient IDs with "19DG"/"20DG" prefixes suggestive of Saudi genomic center nomenclature) and German/European referral patterns, consistent with the multinational, consanguinity-enriched ascertainment typical of ultra-rare AR ciliopathy case series; no formal geographic/ethnic prevalence data exist.
• Sex ratio / age distribution: Not reported as skewed; cohort is pediatric (consistent with severe early-onset presentation).

10. Diagnostics

General PCD diagnostic framework (per ATS/ERS guidelines), adapted for this syndromic form: - Nasal nitric oxide (nNO): Standard PCD screening test; low nNO is typical in structural/axonemal PCD. Its behavior in TP73-CILD47 (an MCC-differentiation, not axonemal-structure, defect) was not explicitly reported in the retrieved data and should be checked directly against the primary paper before asserting a specific nNO value/finding. - High-speed video microscopy (ciliary beat pattern/frequency): Would be expected to show reduced/absent ciliary beating due to markedly reduced cilia number and length, though this is inferred from the cell-biology data (particle-tracking dysfunction) rather than a directly quoted clinical HSVA report. - Transmission electron microscopy (TEM): Reported as essentially normal axonemal ultrastructure (9+2 arrangement, normal outer dynein arms/DNAH5, normal nexin-dynein regulatory complex/GAS8) — an important diagnostic pitfall, since standard TEM-based PCD diagnosis could be falsely reassuring/normal in this gene defect; diagnosis instead rests on reduced MCC numbers and ciliary length (immunofluorescence for FOXJ1/acetylated tubulin) plus genetic testing. - Genetic testing: TP73 sequencing (single-gene or as part of an expanded PCD/ciliopathy gene panel) is the definitive diagnostic approach, especially when the combination of PCD-like respiratory disease plus lissencephaly is present — this combination should specifically trigger TP73 testing given the described disease. WES/WGS are appropriate given the syndromic (multi-organ) presentation and phenotypic novelty. - Brain MRI: Central to diagnosis of the neurological component — frontoanterior-predominant pachygyria/lissencephaly, thin/absent corpus callosum, ± hippocampal dysplasia. - Chest imaging (CT): Bronchiectasis, mucus plugging, atelectasis. - Situs assessment: Notably normal (situs solitus) — this is diagnostically useful as it can distinguish TP73-CILD47/RGMC-spectrum disease from classical PCD, where situs anomalies occur in ~50% of patients due to nodal cilia dysfunction.

Differential diagnosis: - Other RGMC-spectrum disorders: MCIDAS, CCNO, FOXJ1 (also cause reduced MCC numbers with normal axonemal ultrastructure and normal situs; FOXJ1 pathology can also involve hydrocephalus and, in some reports, laterality defects since FOXJ1 also functions in nodal cilia). - Classical structural PCD genes (DNAH5, DNAI1, CCDC39, CCDC40, etc.) — distinguished by abnormal TEM/axonemal structure and higher rate of situs anomalies. - Isolated (non-ciliopathy) lissencephaly syndromes (LIS1/PAFAH1B1, DCX, TUBA1A, ARX) — distinguished by absence of a respiratory/mucociliary phenotype. - Other syndromic ciliopathies with CNS + respiratory overlap (e.g., some CEP-gene ciliopathies) should be considered in the broader differential.

Screening: No population newborn-screening program exists for this ultra-rare condition; prenatal diagnosis/genetic counseling is feasible in known-carrier consanguineous families once a familial variant is identified.

11. Outcome/Prognosis

• Mortality: 1 of 7 reported patients died of respiratory failure at 2 months of age — indicating a potentially high-severity subgroup with neonatal-onset, ventilator-dependent respiratory failure. No formal survival curve/life-expectancy estimate exists given the small cohort.
• Morbidity: Chronic lung disease (bronchiectasis) is expected to be lifelong in survivors, analogous to other PCD forms. Neurodevelopmentally, all surviving patients have moderate-to-severe cognitive impairment and central hypotonia; some have seizure risk.
• Recovery potential: The cortical malformation is a fixed structural defect with no expected anatomical recovery; developmental outcome depends on the degree of associated intellectual disability and access to supportive/rehabilitative therapy. Respiratory disease, as with other PCD, can be stabilized (not cured) with aggressive airway clearance and infection management, though data specific to long-term respiratory trajectory in TP73-CILD47 beyond the initial case series are not yet available.
• Prognostic factors: Severity of the neonatal respiratory presentation (ventilator dependence) appears to correlate with the most severe outcomes (the one death occurred in a neonatal-ventilator-dependent patient); no molecular (variant-type) genotype-severity correlation has yet been established given the small, genetically heterogeneous cohort.

12. Treatment

No disease-specific (TP73-targeted) therapy exists. Management follows standard PCD supportive care, extrapolated from general PCD/RGMC management guidelines, plus standard neurodevelopmental/neurological supportive care for the CNS malformation:

Respiratory — supportive/standard-of-care: - Airway clearance therapy (chest physiotherapy, mechanical airway clearance devices) — NCIT:C15315 (Rehabilitation) / a specific airway-clearance NCIT term should be sourced. - Mucolytics / hypertonic saline nebulization — supportive care, NCIT:C15747 (Supportive Care). - Prophylactic/therapeutic antibiotics for recurrent respiratory infections (e.g., macrolides such as azithromycin, used in general PCD/bronchiectasis management for both antimicrobial and anti-inflammatory effect) — NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to the specific antibiotic class as appropriate. - Ventilatory support in neonatal/severe presentations (NCIT — mechanical ventilation-type intervention term should be sourced specifically). - Otologic management for recurrent otitis media (e.g., tympanostomy tubes) — surgical/procedural, NCIT:C15329 (Surgical Procedure)-family term.

Neurological — supportive: - Physical, occupational, and speech therapy for hypotonia and developmental delay — NCIT:C15302 (Physical Therapy), NCIT:C121351 (Occupational Therapy), NCIT:C159273 (Speech Therapy). - Antiepileptic management if/when seizures manifest — standard pharmacotherapy, agent-specific. - Developmental/early intervention services.

Advanced/experimental therapeutics: None reported or in trials specific to TP73-CILD47 (no ClinicalTrials.gov entries identified in this search for this specific gene-disease pair). Gene therapy is not a near-term realistic option given the dual-organ (lung epithelium + CNS developmental) nature of the defect and the fact that the CNS malformation is a fixed prenatal/perinatal structural lesion rather than an ongoing degenerative process amenable to postnatal correction.

Treatment strategy: Multidisciplinary (pulmonology, neurology, developmental pediatrics, otolaryngology) supportive management; no published treatment algorithm specific to this gene-disease association exists — management should be extrapolated cautiously from general PCD and general lissencephaly/hypotonia care guidelines, explicitly noted as extrapolated rather than disease-specific evidence.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (monogenic developmental disorder) beyond genetic counseling for consanguineous/carrier families with a known familial TP73 variant, and prenatal diagnosis (chorionic villus sampling/amniocentesis with targeted variant testing, or prenatal ultrasound/fetal MRI surveillance for cortical malformation) in at-risk pregnancies once the familial variant is known — NCIT:C15240 (Genetic Counseling).
• Secondary prevention: Early recognition of the combined respiratory + lissencephaly phenotype should prompt TP73 testing to enable earlier diagnosis, respiratory surveillance, and proactive infection management (reducing risk of the bronchiectasis/respiratory-failure trajectory).
• Tertiary prevention: Aggressive airway clearance and infection control aimed at preventing progression to bronchiectasis and respiratory failure in diagnosed patients (extrapolated from general PCD management, not disease-specific evidence).
• Screening: No population-level newborn screening exists; carrier screening is only practical within already-identified affected families/consanguineous populations.
• Immunization: No disease-specific vaccine strategy, though standard respiratory-pathogen vaccination (influenza, pneumococcal, pertussis-containing) is a reasonable general recommendation by analogy to other chronic suppurative lung diseases, though not specifically documented for this condition.

14. Other Species / Natural Disease

No naturally occurring TP73-deficient disease has been reported in non-human species (no OMIA entries or veterinary case reports identified in this search). All non-human data derive from engineered mouse knockout models (see §15) rather than spontaneously occurring animal disease.

15. Model Organisms

Mouse (Mus musculus, NCBITaxon:10090) — Trp73 (mouse ortholog) knockout/conditional models — the primary and extensively characterized model system:

• Trp73-null mice: Recapitulate multiple features of the human dual-organ phenotype, unifying several previously separately-described p73-knockout phenotypes under a single ciliogenesis-defect mechanism: chronic respiratory tract infections due to profound ciliogenesis defects and loss of mucociliary clearance, hydrocephalus, hippocampal dysgenesis, sterility, and chronic middle-ear/sinus inflammation (Nemajerova et al. 2016, Genes Dev, PMID:27257214; Marshall et al. 2016, Cell Rep, PMID:26947080).
• TAp73 specifically (the N-terminal transactivating isoform) was shown to be necessary and sufficient for basal body docking, axonemal extension, and motility during MCC-progenitor differentiation in mouse organotypic airway (tracheal) cultures, and to directly bind and activate FOXJ1, RFX2, RFX3, and the miR-34bc locus (PMID:27257214).
• Ependymal-specific conditional models: Perinatal loss of p73 in ependymal cells leads to aqueductal stenosis and disrupted ependymal planar cell polarity (actin/microtubule cytoskeleton), directly implicating the same TAp73-multiciliogenesis axis in the CNS ventricular-lining phenotype relevant to the human lissencephaly/ventricular findings (Fujitani et al. 2017, Sci Rep 7:12007, PMID:28931858; related work on p73/ependymal PCP and SVZ neurogenic cytoarchitecture from the same research lineage — cite with direct verification of exact PMIDs before KB entry).
• Phenotype recapitulation vs. human disease: The mouse models recapitulate the airway MCC-differentiation defect and mucociliary clearance failure well, and support the mechanistic link between p73 loss and both ependymal/ciliary and cortical-architecture abnormalities. However, mouse Trp73-null models show more prominent hydrocephalus than the reported human cohort (where overt hydrocephalus was largely absent, aside from transient prenatal ventriculomegaly in one patient) — this is a candidate human-model mismatch worth flagging explicitly in any dismech curation (per the project's HUMAN_MODEL_MISMATCH discussion pattern) rather than assuming full concordance between the mouse hydrocephalus phenotype and the milder human ventricular findings.
• In vitro human models: Patient-derived nasal/bronchial air-liquid-interface (ALI) epithelial cultures were the direct human cellular model used in Wallmeier et al. 2021 to demonstrate the MCC-differentiation and ciliary-transport defects described in §6 — this is IN_VITRO (human primary cell) evidence, distinct from the MODEL_ORGANISM (mouse) evidence above, and should be tagged accordingly in any evidence curation.

Resources: MGI (Mouse Genome Informatics) holds the Trp73 knockout allele records; no zebrafish, Drosophila, or C. elegans TP73-ortholog disease models specific to this phenotype were identified in this search.

Summary of Key Ontology Term Suggestions (to be independently OAK-verified before KB entry)

Key Primary Citations (PMIDs)

1. Wallmeier J, Bracht D, Alsaif HS, et al. Mutations in TP73 cause impaired mucociliary clearance and lissencephaly. Am J Hum Genet. 2021;108(7):1318–1329. PMID:34077761 — the founding/only human clinical-genetic case series (7 patients, 5 families).
2. Nemajerova A, Kramer D, Siller SS, et al. TAp73 is a central transcriptional regulator of airway multiciliogenesis. Genes Dev. 2016;30(11):1300–1312. PMID:27257214 — mouse mechanistic model.
3. Companion paper, "Unifying the p73 knockout phenotypes: TAp73 orchestrates multiciliogenesis," Genes Dev. 2016. PMID:27298333 — independent convergent mouse study (verify author list directly before citing).
4. Marshall CB, Mays DJ, Beeler JS, et al. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell Rep. 2016;14(14):2289–2300. PMID:26947080.
5. Fujitani M, et al. Loss of p73 in ependymal cells during the perinatal period leads to aqueductal stenosis. Sci Rep. 2017;7:12007. PMID:28931858 — ependymal/CNS mouse mechanistic model.
6. General PCD context: Zariwala MA, Zhu X, et al., global prevalence/gene-variant analysis, PMID:35051411; ATS/ERS PCD diagnostic guidelines (multiple; verify exact current PMID before citing, as an updated version was found dated 2026 alongside the earlier 2017/2018 versions).

Important caveat for dismech curation: Several of the mechanistic mouse-model PMIDs above (notably the ependymal/PCP lineage of papers) were partially reconstructed from search-result summaries rather than fully verified against the primary abstract text in this pass. Per this project's own DR-verification SOP, every PMID and snippet listed here must be independently re-verified via just fetch-reference and just validate-references before being committed to a KB entry — treat this report as a well-sourced lead set, not pre-verified curation-ready evidence.